Abstracts Archive - Page 2379 of 2425 - ACR Meeting Abstracts

Abstract Number: 640 • 2012 ACR/ARHP Annual Meeting
Association of Body Weight with Cardiovascular Events in Systemic Lupus Erythematosus
George Stojan¹, Homa Timlin², Hong Fang³, Laurence S. Magder⁴ and Michelle Petri³, ¹Division of Rheumatology, Harvard Medical School- Beth Israel Deaconess Medical Center, Boston, MA, ²West Drayton, United Kingdom, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Excessive body mass among healthy subjects carries an increased risk of subsequent cardiovascular (CV) events. In healthy subjects, the relationship between body mass index…
Abstract Number: 641 • 2012 ACR/ARHP Annual Meeting
Study of Anti-Müllerian Hormone and Probability of Pregnancy in 112 Systemic Lupus Erythematosus Patients Exposed or Not to Cyclophosphamide
Nathalie Morel¹, Anne Bachelot², Zeina Chakhtoura², Zahir Amoura¹, Olivier Aumaitre³, Jean-Emmanuel Kahn⁴, Du Boutin⁵, Pierre Duhaut⁶, Dominique Farge⁷, Camille Francès¹, Lionel Galicier⁸, Gaëlle Guettrot-Imbert³, Jean-Robert Harlé⁹, Olivier Lambotte¹⁰, Véronique Le Guern¹¹, Jean-Charles Piette¹², Jacques Pourrat¹³, Karim Sacre¹⁴, Damien Sene¹⁵, Salim Trad¹⁶, Elisabeth Vidal¹⁷, Lamiae Grimaldi¹⁸, Christiane Coussieu¹⁹, Nathalie Costedoat-Chalumeau²⁰ and PLUS²¹, ¹Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²Endocrinology, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ³Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁶Internal Medicine and RECIF, CHU Nord, Amiens, France, ⁷Medicine, EBMT, Paris, France, ⁸Internal Medicine, Hopital Saint Louis, Paris, France, ⁹Internal Medicine, CHU Toulouse, Toulouse, France, ¹⁰Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France, ¹¹Department of Internal Medicine, Cochin Hospital, Paris, France, ¹²Internal Medicine 2, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ¹³Toulouse University Hospital, University of Toulouse, Toulouse, France, ¹⁴Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ¹⁵Internal Medicine, Hopital Lariboisière, Paris, France, ¹⁶Internal Medicine, Hopital Ambroise Paré, Paris, France, ¹⁷Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ¹⁸Société Laser, Paris, France, ¹⁹Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²⁰Internal Medicine, Hopital Cochin, Paris, France, ²¹Paris, France
Background/Purpose: Cyclophosphamide (CYC), a drug commonly used in systemic lupus erythematosus (SLE), is associated with a risk of ovarian failure resulting in infertility. In the…
Abstract Number: 642 • 2012 ACR/ARHP Annual Meeting
Effects of Treatment On the Expression of CCL2 and CXCL10 in Systemic Lupus Erythematosus Patients
Paul R. Dominguez-Gutierrez¹, Angela Ceribelli¹, Minoru Satoh², Eric S. Sobel³, Westley H. Reeves⁴ and Edward K.L. Chan¹, ¹Oral Biology, University of Florida, Gainesville, FL, ²Medicine, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Several candidate biomarkers for Systemic Lupus Erythematosus (SLE) have been reported including STAT1, ADAR, CCL2, CXCL10, and miR-146a. This study examines the effects of…
Abstract Number: 643 • 2012 ACR/ARHP Annual Meeting
Clinical Characteristics for Future Development of Systemic Lupus Erythematosus in Korean Patients with Idiopathic Thrombocytopenic Purpura
Yeon-Ah Lee¹, Somi Kim¹, Ran Song² and Sang-Hoon Lee², ¹Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ²Rheumatology, Hospital at GANGDONG, Kyung Hee University, Seoul, South Korea
Background/Purpose: Systemic lupus erythematosus (SLE), a chronic inflammatory autoimmune disease capable of exhibiting virtually any clinical symptoms, occasionally presents itself with thrombocytopenic purpura as an…
Abstract Number: 644 • 2012 ACR/ARHP Annual Meeting
Pulmonary Hypertension in Systemic Lupus Erythematosus: A 6-Year Follow-up Study Cohort
Claudia Hübbe-Tena¹, Selma Gallegos-Nava¹, Rafael Bojalil² and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) may present hemodynamic alterations including pulmonary hypertension (PH). Echocardiography (ECHO) is a noninvasive imaging technique useful to classify pulmonary hypertension…
Abstract Number: 645 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Inflammatory Mediators Mark Impending Systemic Lupus Erythematosus Disease Flare in European-American Lupus Patients Who Receive Influenza Vaccination
Melissa E. Munroe¹, Jourdan R. Anderson², Joan T. Merrill³, Joel M. Guthridge⁴, Virginia C. Roberts⁴, Gillian M. Air⁵, Linda F. Thompson⁶ and Judith A. James⁷, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Biochemistry, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a multifaceted autoimmune disease denoted by immune dysregulation that contributes to increased morbidity and mortality in part due to infectious complications. Vaccination…
Abstract Number: 646 • 2012 ACR/ARHP Annual Meeting
Comparison of the Lupusqol and SF-36 Scores As Valid Measures of Change in Health Related Quality of Life
Zahi Touma¹, Murray B. Urowitz², Dominique Ibanez², Shahrzad Taghavi-Zadeh³ and D. D. Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The LupusQoL questionnaire is a disease-specific instrument for adults with lupus while the short form-36 (SF-36) is a generic questionnaire. We aimed to compare…
Abstract Number: 647 • 2012 ACR/ARHP Annual Meeting
Adjusted Framingham Risk Factor Scoring for Systemic Lupus Erythematosus: Results from an Inception Cohort Followed for Eight Years
Murray B. Urowitz¹, Dominique Ibanez¹, D. D. Gladman², SLICC³ and Systemic Lupus International Collaborating Clinics (SLICC)³, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose : There is a high prevalence of premature atherosclerosis among patients with SLE, with a risk 7-9 times that of the general population. The…
Abstract Number: 648 • 2012 ACR/ARHP Annual Meeting
Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus: Incidence Over a Ten Year Period
D. D. Gladman¹, Dominique Ibanez², Murray B. Urowitz² and SLICC³, ¹Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: A large multicentre multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. The purpose of this study was to…
Abstract Number: 649 • 2012 ACR/ARHP Annual Meeting
Increased Male-to-Female Ratio in Children Born to Women with Systemic Lupus Erythematosus
Evelyne Vinet¹, Sasha Bernatsky², Mohammed Kaouache², Emil P. Nashi³, Christian A. Pineau³, Ann E. Clarke⁴, Robert W. Platt⁵, Meggan C. Mackay⁶ and Cynthia Aranow⁷, ¹McGill University Health Centre, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, ⁷Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Recent experimental evidence suggests that anti-DNA antibodies, cross-reacting with brainstem neuronal receptors, induce apoptosis and cause a marked preferential loss of female foetuses in…
Abstract Number: 650 • 2012 ACR/ARHP Annual Meeting
Clinical Variables Associated with Thrombosis At Systemic Lupus Erythematosus Diagnosis. Differences Between Patients with Positive/Negative Lupus Anticoagulant
Andrea Hinojosa-Azaola¹, Alba Cicero-Casarrubias¹, Mario César Ocampo-Torres¹, Juanita Romero-Díaz¹ and Jorge Sánchez-Guerrero², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Thrombosis in patients with Systemic Lupus Erythematosus (SLE) is a major cause of morbidity, it occurs in 9-37%, at younger age, and it represents…
Abstract Number: 611 • 2012 ACR/ARHP Annual Meeting
Impaired Diffusion Tensor Imaging Findings in the Corpus Callosum and Cingulum May Underlie Impaired Learning and Memory Abilities in Systemic Lupus Erythematosus
Daphna Paran¹, Elissa Ash², Ira Litinsky¹, Valerie Aloush¹, Marina Anouk¹, Dan Caspi³, Talma Hendler⁴ and Irit Shapira-Lichter⁴, ¹Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, ²Neurology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, ³Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁴Functional Brain Center, Wohl Institute for Advanced Imaging, Tel-Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel
Background/Purpose: Memory impairment is prevalent in systemic lupus erythematosus (SLE), however the pathogenesis is unknown. In a previous functional Magnetic Resonance Imaging (MRI) study we…
Abstract Number: 612 • 2012 ACR/ARHP Annual Meeting
Thrombosis Recurrence in Systemic Lupus Erythematosus Patients with and without Antiphospholipid Antibodies
Ibrahim AlHomood¹, D. D. Gladman², Dominique Ibanez³ and Murray B. Urowitz³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To determine the outcome of thrombotic events in the presence and absence of antiphospholipid antibodies (aPL) in patients with systemic lupus erythematosus (SLE).…
Abstract Number: 613 • 2012 ACR/ARHP Annual Meeting
Serum Level of Syndecan-1 Is Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
In-Woon Baek¹, Ki-Jo Kim², Ji-Young Kim³, Su-Jung Park³, Chong-Hyeun Yoon⁴, Wan-Uk Kim⁵ and Chul Soo Cho⁶, ¹Internal medicine, Catholic University of Korea, Callege of Medicine, Seoul, South Korea, ²Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, Research Institute of Bone & Joint Diseases, Catholic University of Korea, Seoul, South Korea, ⁴Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁵Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶St Marys Hospital, Seoul, South Korea
Background/Purpose: Syndecan-1(SDC1), a transmemebrane heparan-sulfate glycoprotein, is predominantly expressed by plasma cells and is a receptor for a proliferation-inducing ligand (APRIL). SDC-1 is readily shed…
Abstract Number: 614 • 2012 ACR/ARHP Annual Meeting
Predictors of Systemic Lupus Erythematosus Flares: Baseline Disease Activity and Demographic Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials
Ronald F. van Vollenhoven¹, Michelle Petri², Roger A. Levy³, Sandra V. Navarra⁴, Jill P. Buyon⁵, Z. John Zhong⁶, William W. Freimuth⁶ and Ricard Cervera⁷, ¹Karolinska University Hospital, Stockholm, Sweden, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Internal Medicine, Univ Estado Do Rio De Janeiro, Rio de Janeiro, Brazil, ⁴University of Santo Tomas Hospital, Manila, Philippines, ⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: Predicting which SLE patients are at increased risk for clinically meaningful flares may be useful in making management decisions. The purpose of this analysis was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].